Glioblastoma: New First-Line Treatment Regimen Provides Hope

​A phase 3 clinical trial has shown that a regimen consisting of lomustine and temozolomide in combination with radiotherapy can improve survival for patients with previously untreated glioblastoma with MGMT promoter methylation.Glioblastoma, the most common form of primary brain tumor, is highly aggressive and extremely deadly, with a five-year survival rate of only 5.6%. Standard treatment is radiotherapy followed by chemotherapy with temozolomide, an alkylating agent (a drug that interferes w...
Continue reading

New Therapeutic Target in Glioblastoma: FGL2

​In an immune regulatory protein that promotes the progression of glioblastoma multiforme (GBM) by suppressing the immune system, researchers at the University of Texas MD Anderson Cancer Center have found a potential therapeutic target.Until now, little research has been done about the role of immune-associated genes in the progression of brain tumors. "Classical wisdom is that brain tumor progression is linked to oncogene activation and tumor suppressor gene inactivation; however, genetic and ...
Continue reading

Grouped MicroRNAs Fight Glioblastomas

MicroRNAs—strings of nucleotides that bind to and destroy messenger RNA to prevent the production of certain proteins—have been discovered to play an important role in cancer and other diseases. However, in previous preclinical trials, microRNA cancer treatments lacked efficacy.In recent developments, scientists at Brigham and Women's Hospital and Harvard Medical School grouped micro-RNA molecules together, encoding them in a small, artificial gene, and then infiltrated cancer cells to overprodu...
Continue reading

A Way to Avoid Glioblastoma Invasion

Researchers' discovery that forces enhancing fluid flow within a glioblastoma's interstitial spaces can increase the cancer's invasion of surrounding tissue has critical implications for a new drug delivery technique. However, the investigators have also found a solution to this problem.The most common form of brain cancer, glioblastoma is also the most malignant. Because it is characterized by invasion into the surrounding brain tissue, it is highly difficult to treat and invariably relapses. "...
Continue reading

New Treatment Targets Chemotherapy-Resistant Brain Cancer

Researchers have demonstrated the efficacy of a new treatment targeting genetic mutations in patients with chemotherapy-resistant secondary glioblastoma (sGBM), a rare and deadly form of brain cancer.Low-grade gliomas progress into sGBM, which has limited treatment options and a 5-year survival rate under 10%. Secondary glioblastoma is treated with temozolomide (TMZ), a chemotherapy drug. Upon relapse, which happens in most patients, genetic mutations enable sGBM tumors to resist the drug's effe...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.